Abstracts tagged "fracture risk and osteoporosis"

Abstract Number: 2230 • 2019 ACR/ARP Annual Meeting
Applicability of FRAX in Clinical Practice: 10-year Results
Carla Marco-Pascual¹, Maribel Mora ², Xavier González-Giménez ¹, Pilar Medina ³, Maria-Marta Bianchi ⁴, Pilar Santo ⁵ and Carmen Gomez-Vaquero ⁶, ¹Hospital Universitari de Bellvitge. Rheumatology Department, Barcelona, Spain, ²Hospital Universitari de Bellvitge, Hospitalet de Llobregat, Spain, ³Hospital Universitari Vall d'Hebrón. Radiology Department, Barcelona, Spain, ⁴Consorci Sanitari de Terrassa. Rheumatology Department, Barcelona, Spain, ⁵Parc sanitari Sant Joan de Déu de Sant Boi. Rheumatology Department, Barcelona, Spain, ⁶Hospital Universitari de Bellvitge. Rheumatology Department, El Prat, Spain
Background/Purpose: Applicability of FRAX in Clinical Practice. Results at 10 yearsTo evaluate the applicability of: 1) the fracture risk thresholds that we proposed in 2013…
Abstract Number: 1182 • 2018 ACR/ARHP Annual Meeting
The Disproportionate High Risk of Re-Fracture after Osteoporotic Treatment in Patients with Autoimmune Diseases
Wen-Nan Huang¹, Yi-Ming Chen¹, Wei-Ting Hung², Yu-Wan Liao³ and Yi-Hsing Chen¹, ¹Division of Allergy, Immunology and Rheumatology, Taichung Veterans General Hospital, Taichung, Taiwan, ²Division of Allergy, Immunology and Rheumatology, Department of Internal Medicine, Taichung Veterans General Hospital, Taichung, Taiwan, ³Taichung Veterans General Hospital, Taichung, Taiwan
Background/Purpose: Patients with autoimmune diseases are associated with an increased risk of osteoporotic fracture. Anti-osteoporotic treatment could diminish re-fracture rates in post-menopause women. However, treatment…
Abstract Number: 2318 • 2018 ACR/ARHP Annual Meeting
Fracture Liaison Service in an Open Health System: Outcomes and Challenges
Donna Jose¹, Karina Torralba², Christina Downey², Micah Yu¹ and Lorena Salto³, ¹Internal Medicine, Loma Linda University Medical Center, Loma Linda, CA, ²Loma Linda University Medical Center, Loma Linda, CA, ³Loma Linda University, Loma Linda, CA
Background/Purpose: The “osteoporosis care gap” is noted by findings that 80% of patients do not receive treatment after an initial fracture. An initial fracture portends…
Abstract Number: 319 • 2017 ACR/ARHP Annual Meeting
The Placebo-Controlled Fracture Study in Postmenopausal Women with Osteoporosis: The Foundation Effect of Rebuilding Bone with One Year of Romosozumab Leads to Continued Lower Fracture Risk after Transition to Denosumab
Felicia Cosman¹, Daria B Crittenden², Serge Ferrari³, Aliya Khan⁴, Nancy E Lane⁵, Kurt Lippuner⁶, Toshio Matsumoto⁷, Cassandra E Milmont², Cesar Libanati⁸ and Andreas Grauer², ¹Helen Hayes Hospital, West Haverstraw, and Columbia University, New York, NY, ²Amgen Inc., Thousand Oaks, CA, ³Geneva University Hospital, Geneva, Switzerland, ⁴McMaster University, Hamilton, ON, Canada, ⁵UC Davis Medical Center, Sacramento, CA, ⁶Osteoporosis Policlinic, Inselspital, Bern University Hospital and University of Bern, Bern, Switzerland, ⁷University of Tokushima, Tokushima, Japan, ⁸UCB Pharma, Brussels, Belgium
Background/Purpose: Romosozumab (Romo), a sclerostin antibody, has a dual effect of increasing bone formation and decreasing bone resorption. In the FRAME study, one year of…
Abstract Number: 1213 • 2017 ACR/ARHP Annual Meeting
Prediction Model for the Two-Year Risk of Fracture Among Older US Women
Annette Adams¹, Akhila Balasubramanian², Hui Zhou³, Robert Platt⁴, Deborah Wenkert⁵, Steven Jacobsen³ and Eric Johnson⁶, ¹Kaiser Permanente Southern California, Pasadean, CA, ²Amgen Inc., Thousand Oaks, CA, ³Kaiser Permanente Southern California, Pasadena, CA, ⁴McGill University, Montreal, QC, Canada, ⁵Wenkert & Young, LLC, Thousand Oaks, CA, ⁶Kaiser Permanente Northwest, Portland, OR
Background/Purpose: Current algorithms for identifying patients at high risk of fracture focus on long-term risk. We developed simple 10- and 3-predictor models and points-based risk…
Abstract Number: 1228 • 2017 ACR/ARHP Annual Meeting
Postmenopausal Breast Cancer Patients on Aromatase Inhibitor Therapy and Their Increased Risk of Fragility Fracture
Anna Lafian¹, Julia Suh² and Karina Torralba³, ¹Internal Medicine, Arrowhead Regional Medical Center, Colton, CA, ²Internal Medicine, Loma Linda University, Loma Linda, CA, ³Internal Medicine/Rheumatology, Loma Linda University, Loma Linda, CA
Background/Purpose: Postmenopausal women with breast cancer have higher osteoporosis risk due to declining estrogen levels and use of aromatase inhibitors (AIs). The American Society of…
Abstract Number: 1230 • 2017 ACR/ARHP Annual Meeting
Comparative Study of Frax® Score in Ecuadorian Population
Genessis Maldonado¹, Carlos Paredes¹, Roberto Guerrero¹, Maricarmen Mieles¹, Maria Jose Intriago¹, O Messina² and Carlos Ríos³, ¹Universidad Espiritu Santo, Guayaquil, Ecuador, ²Hospital Argerich, Buenos Aires, Argentina, ³Centro de Reumatología y Rehabilitación CERER, Guayaquil, Ecuador
Background/Purpose: Osteoporosis is a systemic skeletal disease characterized by a decrease in bone mineral density with alterations in bone microarchitecture and an increased risk of…
Abstract Number: 2517 • 2017 ACR/ARHP Annual Meeting
The Usefulness of Trabecular Bone Score in Assessing the Bone Strength and Fracture Risk of Patients with Ankylosing Spondylitis
Seoung Wan Nam¹, Yoon-Kyoung Sung², Dam Kim², Soo-Kyung Cho³, Yoonah Song⁴, Yun Young Choi⁵ and Tae-Hwan Kim², ¹Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, Korea, Republic of (South), ²Hanyang University Hospital for Rheumatic Diseases, Seoul, Korea, Republic of (South), ³Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, Korea, Republic of (South), ⁴Department of Radiology, Hanyang University Hospital for Rheumatic Diseases, Seoul, Korea, Republic of (South), ⁵Department of Nuclear Medicine, Hanyang University Medical Center, Seoul, Korea, Republic of (South)
Background/Purpose: Ankylosing spondylitis (AS) is a disease characterized by spinal osteoproliferation (syndesmophytosis) and the general trabecular bone loss with increased fracture risk. Syndesmophyts in spine…
Abstract Number: 2777 • 2017 ACR/ARHP Annual Meeting
Factors Associated with Readiness for Adopting Osteoporosis Treatment Change
Maria I. Danila¹, Elizabeth J. Rahn², Amy S. Mudano¹, Ryan C. Outman³, Peng Li⁴, David T. Redden⁴, Fred A. Anderson⁵, Susan L. Greenspan⁶, Andrea Z. LaCroix⁷, Jeri W. Nieves⁸, Stuart L. Silverman⁹, E.S. Siris¹⁰, Nelson B. Watts¹¹, Sigrid Ladores¹², Karen Meneses¹², Jeffrey R. Curtis³ and Kenneth Saag³, ¹University of Alabama at Birmingham, Birmingham, AL, ²Department of Medicine, Division of Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ³Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁴Department of Biostatistics, University of Alabama at Birmingham, Birmingham, AL, ⁵University of Massachusetts Medical School, Worcester, MA, ⁶Medicine, University of Pittsburgh, Pittsburgh, PA, ⁷Group Health Cooperative, Seattle, WA, ⁸Helen Hayes, West Haverstraw, NY, ⁹Cedars-Sinai Medical Center, Los Angeles, CA, ¹⁰Columbia University Medical Center, New York, NY, ¹¹University of Cincinnati, Cincinnati, OH, ¹²Nursing, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Understanding factors associated with the readiness for adopting osteoporosis treatment change may inform the design of behavioral interventions to improve osteoporosis treatment uptake in…
Abstract Number: 332 • 2016 ACR/ARHP Annual Meeting
A Comparison of Electronic and Manual Fracture Risk Assessment Tools in Screening US Veterans at Risk for Osteoporosis
Tyler Williams¹, Phillip Lawrence², Jacob Crook³, Richard Nelson³, Joanne Lafleur⁴ and Grant W. Cannon⁵, ¹Salt Lake City VA Medical Center and University of Utah Department of Internal Medicine, Salt Lake City, UT, ²Salt Lake City VA Medical Center and Roseman University of Health Sciences, Salt Lake City, UT, ³University of Utah Division of Epidemiology and Salt Lake City VA Medical Center, Salt Lake City, UT, ⁴University of Utah Department of Pharmacotherapy and Salt Lake City VA Medical Center, Salt Lake City, UT, ⁵Salt Lake City VA Medical Center and University of Utah Division of Rheumatology, Salt Lake City, UT
Background/Purpose: Osteoporosis-related fractures contribute to increased morbidity and mortality in those affected and substantial economic burden to society. Effective screening for osteoporosis with fracture risk…
Abstract Number: 343 • 2015 ACR/ARHP Annual Meeting
Efficacy of Odanacatib in Postmenopausal Women with Osteoporosis: Subgroup Analyses of Data from the Phase 3 Long-Term Odanacatib Fracture Trial
Kenneth G. Saag¹, Peter Alexandersen², Claude-Laurent Benhamou³, Nigel Gilchrist⁴, Johan Halse⁵, E. Michael Lewiecki⁶, Kurt Lippuner⁷, Michael McClung⁸, Masataka Shiraki⁹, Carolyn A. DaSilva¹⁰, Nadia Verbruggen¹¹, Boyd B. Scott¹⁰ and Antonio Lombardi¹⁰, ¹University of Alabama at Birmingham, Birmingham, AL, ²Center for Clinical and Basic Research, Vejle, Denmark, Ballerup, Denmark, ³Hôpital d’Orléans-la-Source, Orléans, France, Orleans, France, ⁴The Princess Margaret Hospital, Christchurch, New Zealand, Christchurch, New Zealand, ⁵Osteoporoseklinikken, Oslo, Norway, Oslo, Norway, ⁶New Mexico Clinical Research & Osteoporosis Center, Albuquerque, New Mexico, USA, Albuquerque, NM, ⁷Bern University Hospital, Bern, Switzerland, Bern, Switzerland, ⁸Oregon Osteoporosis Center, Portland, Oregon, USA, Portland, OR, ⁹Research Institute and Practice for Involutional Diseases, Nagano, Japan, Nagano, Japan, ¹⁰Merck & Co., Inc, Kenilworth, NJ, USA, Kenilworth, NJ, ¹¹MSD Europe Inc., Brussels, Belgium, Brussels, Belgium
Background/Purpose: Odanacatib (ODN), a selective oral inhibitor of cathepsin K, is in development for the treatment of osteoporosis. In the Phase 3, Long-Term Odanacatib Fracture…
Abstract Number: 366 • 2015 ACR/ARHP Annual Meeting
Cost-Effective Osteoporosis Treatment Intervention Thresholds Based on FRAX in Portugal
Andréa Marques¹, Oscar Lourenço², Ortsäter Gustaf³, Fredrik Borgström³ and Jose Da Silva⁴, ¹Rheumatology, Centro Hospitalar Universitário de Coimbra, Coimbra, Portugal, ²Centro de Estudos e Investigação em Saúde da Universidade de Coimbra, Faculty of Economics. University of Coimbra, Coimbra, Portugal, ³Quantify Research, Stockholm, Sweden, ⁴Faculty of Medicine. University of Coimbra, Coimbra, Portugal
Background/Purpose: The aim of the present study was to identify the FRAX®Port (FRAX® validated for Portugal) ten-year major and hip osteoporotic fracture probabilities, above which…
Abstract Number: 370 • 2015 ACR/ARHP Annual Meeting
Impact of Didactic Lecture on Osteoporosis Screening and Fracture Risk Assessment Among House Staff
Meghan Greenfield¹, Jordan Brodsky² and Erin Patton³, ¹Rheumatology, University Of Washington, Seattle, WA, ²Medicine, Albert Einstein College of Medicine, Bronx, NY, ³Medicine/Rheumatology, Mount Sinai Beth Israel, New York, NY
Background/Purpose: It has been estimated that 12 million Americans over the age of 50 have osteoporosis. Of those, only 30% of eligible women age 65…
Abstract Number: 381 • 2015 ACR/ARHP Annual Meeting
Associations Between Vitamin D Insufficiency, Osteoporotic Fractures and Comorbidites
Eugenio Chamizo Carmona¹, Juan Jose Aznar Sánchez^1,2, Raul Veroz Gonzalez², Tamara Libertad Rodriguez Araya¹, Piter José Cossio Jimenez² and Sara María Rojas Herrera³, ¹Rheumatology, Hospital de Mérida, Mérida, Spain, ²Hospital de Mérida, Mérida, Spain, ³Rheumatolotgy, Hospital de Mérida, Mérida, Spain
Background/Purpose: Vitamin D deficiency is highly prevalence, especially in adults and elderly population. There is controversy about its relationship with increased cardiovascular risk, osteoporosis and…
Abstract Number: 2254 • 2014 ACR/ARHP Annual Meeting
Changes in Subject Characteristics in the Denosumab Pivotal Fracture Trial and Its Extension for up to 8 Years
JD Adachi¹, CJF Lin², PR Ho², MA Bolognese³, HG Bone⁴, P Hadji⁵, S Papapoulos⁶, C Recknor⁷, NS Daizadeh², P Dakin², RB Wagman² and S Ferrari⁸, ¹McMaster University, Hamilton, ON, Canada, ²Amgen Inc., Thousand Oaks, CA, ³Bethesda Health Research Center, Bethesda, MD, ⁴Michigan Bone and Mineral Clinic, Detroit, MI, ⁵Philipps-University of Marburg, Marburg, Germany, ⁶Leiden University Medical Center, Leiden, Netherlands, ⁷United Osteoporosis Centers, Gainesville, GA, ⁸Geneva University Hospital, Geneva, Switzerland
Background/Purpose: Changes in demographics of study population enrolled in long-term osteoporosis clinical trials may affect interpretation of efficacy/safety outcomes. Denosumab is being evaluated for up…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].